Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628190 | 0.98 | KMT2A (0.46) | CYP2D6NFKB1BLMNPSR1LMNA | |
| SCHEMBL21724579 | 0.83 | FAAH (0.51) | KMT2AMEN1ALDH1A1ALOX15TSHR | |
| SCHEMBL3976246 | 0.83 | LMNA (0.52) | CYP2D6NFKB1BLMNPSR1LMNA | |
| SCHEMBL21724159 | 0.82 | FAAH (0.54) | KMT2AMEN1ALDH1A1ALOX15TSHR | |
| SCHEMBL21724577 | 0.82 | FAAH (0.54) | KMT2AMEN1ALDH1A1ALOX15TSHR | |
| SCHEMBL21724599 | 0.82 | FAAH (0.54) | KMT2AMEN1ALDH1A1ALOX15TSHR | |
| SCHEMBL3629338 | 0.82 | FOLH1 (0.42) | KMT2AMEN1FOLH1HDAC3HDAC4 | |
| SCHEMBL3717425 | 0.81 | SLC6A5 (0.45) | CYP2D6NFKB1LMNATHRBKMT2A | |
| SCHEMBL8439259 | 0.81 | NMT1 (0.42) | CYP2D6NFKB1BLMNPSR1LMNA | |
| SCHEMBL27535723 | 0.81 | SLC6A5 (0.45) | CYP2D6NFKB1LMNATHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522916-B2 | A1 adenosine receptor antagonists | WILSON CONSTANCE NEELY (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140031375-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | WILSON CONSTANCE NEELY (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2222676-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009086077-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1636229-A4 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-7247639-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1636229-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA3, ADORA2A | CYP2D6 1207/4885NFKB1 3046/4885BLM 1497/4885 |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | HRH3, HRH1, HRH2 | CYP2D6 1558/4885NFKB1 1572/4885BLM 2968/4885 |
| US-20140031375-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | CYP2D6 604/4885NFKB1 2283/4885BLM 2210/4885 |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | CYP2D6 1282/4885NFKB1 3773/4885BLM 1894/4885 |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA3, ADORA2A | CYP2D6 1213/4885NFKB1 3518/4885BLM 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.